Akebia Therapeutics Inc. [NASDAQ: AKBA] closed the trading session at $3.24 on 03/25/21. The day’s price range saw the stock hit a low of $2.96, while the highest price level was $3.25. The company report on March 25, 2021 that Akebia Therapeutics Announces Poster Presentations and Educational Symposium at National Kidney Foundation 2021 Virtual Spring Clinical Meetings.
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that it will present data at the National Kidney Foundation 2021 Spring Clinical Meetings (NKF SCM21), which takes place virtually April 6-10, 2021.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Abstracts are now available online in the NKF SCM21 Abstract and ePoster Gallery: https://casehippo.com/spa/symposium/national-kidney-foundation-2021-spring-clinical-meetings/event/gallery/browser.
The stocks have a year to date performance of 15.71 percent and weekly performance of -2.70 percent. The stock has been moved at 27.56 percent over the last six months. The stock has performed -24.30 percent around the most recent 30 days and changed 7.64 percent over the most recent 3-months.
If compared to the average trading volume of 6.85M shares, AKBA reached to a volume of 5895720 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Akebia Therapeutics Inc. [AKBA]:
Cantor Fitzgerald have made an estimate for Akebia Therapeutics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 08, 2021. The new note on the price target was released on January 29, 2021, representing the official price target for Akebia Therapeutics Inc. stock. Previously, the target price had yet another drop from $18 to $15, while Needham kept a Buy rating on AKBA stock. On August 06, 2019, analysts decreased their price target for AKBA shares from 19 to 17.
The Average True Range (ATR) for Akebia Therapeutics Inc. is set at 0.29, with the Price to Sales ratio for AKBA stock in the period of the last 12 months amounting to 1.60. The Price to Book ratio for the last quarter was 1.89, with the Price to Cash per share for the same quarter was set at 1.84.
AKBA stock trade performance evaluation
Akebia Therapeutics Inc. [AKBA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.70. With this latest performance, AKBA shares dropped by -24.30% in over the last four-week period, additionally plugging by 27.56% over the last 6 months – not to mention a drop of -57.65% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AKBA stock in for the last two-week period is set at 42.64, with the RSI for the last a single of trading hit 40.99, and the three-weeks RSI is set at 44.56 for Akebia Therapeutics Inc. [AKBA]. The present Moving Average for the last 50 days of trading for this stock 3.72, while it was recorded at 3.31 for the last single week of trading, and 5.69 for the last 200 days.
Akebia Therapeutics Inc. [AKBA]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Akebia Therapeutics Inc. [AKBA] shares currently have an operating margin of -88.35 and a Gross Margin at +38.21. Akebia Therapeutics Inc.’s Net Margin is presently recorded at -129.85.
Return on Total Capital for AKBA is now -59.50, given the latest momentum, and Return on Invested Capital for the company is -88.49. Return on Equity for this stock declined to -119.39, with Return on Assets sitting at -54.19. When it comes to the capital structure of this company, Akebia Therapeutics Inc. [AKBA] has a Total Debt to Total Equity ratio set at 51.00. Additionally, AKBA Total Debt to Total Capital is recorded at 33.77, with Total Debt to Total Assets ending up at 19.61. Long-Term Debt to Equity for the company is recorded at 48.87, with the Long-Term Debt to Total Capital now at 32.36.
Reflecting on the efficiency of the workforce at the company, Akebia Therapeutics Inc. [AKBA] managed to generate an average of -$1,011,760 per employee. Receivables Turnover for the company is 8.76 with a Total Asset Turnover recorded at a value of 0.42.Akebia Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.70 and a Current Ratio set at 2.00.
Earnings per share (EPS) analysis for Akebia Therapeutics Inc. [AKBA] stock
With the latest financial reports released by the company, Akebia Therapeutics Inc. posted -0.47/share EPS, while the average EPS was predicted by analysts to be reported at -0.62/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 24.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AKBA.